HER2 Support Group Forums - View Single Post - Info about A/C sensitivity in Her2 patients

al from Canada · 12-10-2005, 09:19 PM

Thanks Scott,
There was a session on this at SABCS and TOPO-II is one of the growing number of markers used to predict the efficacy of various treatments but also as a diagnostic tool to determine which targetted therapy should be used. It was very clear that the future of the traditional slash and burn chemos is questionable in light of the emergance of many targetted therapies which are based upon genetic profiling. What I didn't know was that adriamycin is actually treatment that targets the TOPO-II gene. Therefore, there is a co-relation between TOPO-II expression and the propencity towards cardiac (LVF) episodes. There was also a relationship between HER2 overexpression, TOPO-II overxpression and the response rate to herceptin both with and without adriamycin. As we know, current molecular targets that are cosely associated with the HER2 target are: HER1 & 3, ER, PR, COX2, P53, P13K, ALK, VEGF......just to mention a few. What is evident is a growing number of molecular targetted compounds, being introduced through the clinical trial pipeline.

Two of the most notable from the past few days are Lapatinib (TYKER), a HER1 and HER2 receptor antagonist and Avastin which is a Vascular epidermal growth factor (VEGF) anti-angiogenic compound. The results of Herceptin + avastin trial were nothing short of spectacular as their is a close co-relation between HER2 and VEGF. More on this later......
Regards,
Al

12-10-2005, 09:19 PM	#2
al from Canada Senior Member Join Date: Jul 2005 Location: Ontario, Canada Posts: 722	from SABCS Thanks Scott, There was a session on this at SABCS and TOPO-II is one of the growing number of markers used to predict the efficacy of various treatments but also as a diagnostic tool to determine which targetted therapy should be used. It was very clear that the future of the traditional slash and burn chemos is questionable in light of the emergance of many targetted therapies which are based upon genetic profiling. What I didn't know was that adriamycin is actually treatment that targets the TOPO-II gene. Therefore, there is a co-relation between TOPO-II expression and the propencity towards cardiac (LVF) episodes. There was also a relationship between HER2 overexpression, TOPO-II overxpression and the response rate to herceptin both with and without adriamycin. As we know, current molecular targets that are cosely associated with the HER2 target are: HER1 & 3, ER, PR, COX2, P53, P13K, ALK, VEGF......just to mention a few. What is evident is a growing number of molecular targetted compounds, being introduced through the clinical trial pipeline. Two of the most notable from the past few days are Lapatinib (TYKER), a HER1 and HER2 receptor antagonist and Avastin which is a Vascular epidermal growth factor (VEGF) anti-angiogenic compound. The results of Herceptin + avastin trial were nothing short of spectacular as their is a close co-relation between HER2 and VEGF. More on this later...... Regards, Al __________________ Primary care-giver to and advocate for Linda, who passed away April 27, 2006.